Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 2/2017

01-08-2017 | General Gynecology

Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue

Authors: Vanessa Toderow, Martina Rahmeh, Simone Hofmann, Verena Kirn, Sven Mahner, Udo Jeschke, Viktoria von Schönfeldt

Published in: Archives of Gynecology and Obstetrics | Issue 2/2017

Login to get access

Abstract

Purpose

The nuclear hormone receptor estrogen receptor α (ERα) is pivotal for numerous processes in the cell. As a transcription factor, it regulates eukaryotic gene expression and affects cellular proliferation and differentiation in target tissues. Moreover, ERα is known for its influence on various gynecological diseases and carcinogenesis. Since its expression is often altered in diseased tissues and this alteration was found to be caused by hypermethylation of the ESR1 promotor region in cancer, including breast and colorectal cancer, the aim of this study is to elucidate if the expression of ERα is also regulated epigenetically in endometriosis and endometrial cancer.

Methods

Using real-time methylation-specific PCR (rt-MSP), we examined endometrial and endometriotic tissues as well as five endometrial cancer cell lines and compared the methylation status with the actual expression of ERα.

Results

The results of our study indicate that, though its expression is altered in endometrial and endometriotic tissue, ERα is not regulated by methylation of the promotor region in endometriosis. In contrast, three of the five endometrial cancer cell lines are methylated in the promotor region of ESR1.

Conclusions

Thus, further investigation of the connection between ERα and endometrial cancer will be the next step.
Literature
1.
Ali SH, O’donnell AL, Mohamed S et al (2004) Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: inhibition of growth and angiogenic factors. Gynecol Oncol 95:637–645CrossRefPubMed
2.
Berger U, Mcclelland RA, Wilson P et al (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Can Res 51:239–244
3.
Bloski T, Pierson R (2008) Endometriosis and chronic pelvic pain: unraveling the mystery behind this complex condition. Nurs Women’s Health 12:382–395CrossRef
4.
Bopp B, Shoupe D (1993) Luteal phase defects. J Reprod Med 38:348–356PubMed
5.
Cunha-Filho JS, Gross JL, Bastos De Souza CA et al (2003) Physiopathological aspects of corpus luteum defect in infertile patients with mild/minimal endometriosis. J Assist Reprod Genet 20:117–121CrossRefPubMedPubMedCentral
6.
Eads CA, Lord RV, Kurumboor SK et al (2000) Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Can Res 60:5021–5026
7.
Eeckhoute J, Keeton EK, Lupien M et al (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Can Res 67:6477–6483CrossRef
8.
Elledge RM, Green S, Pugh R et al (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111–117CrossRefPubMed
9.
Engemise SL, Willets JM, Taylor AH et al (2011) Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol 157:101–106CrossRefPubMed
10.
Esteller M, Corn PG, Baylin SB et al (2001) A gene hypermethylation profile of human cancer. Can Res 61:3225–3229
11.
Harder J, Engelstaedter V, Usadel H et al (2009) CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer 100:360–365CrossRefPubMedPubMedCentral
12.
Holmes KA, Song JS, Liu XS et al (2008) Nk3–1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Can Res 68:7380–7385CrossRef
13.
Holst F, Hoivik EA, Gibson WJ et al (2016) Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep 6:25521CrossRefPubMedPubMedCentral
14.
15.
Hurtado A, Holmes KA, Geistlinger TR et al (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–666CrossRefPubMedPubMedCentral
16.
Issa JP, Ottaviano YL, Celano P et al (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7:536–540CrossRefPubMed
17.
Issa JP, Zehnbauer BA, Civin CI et al (1996) The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Can Res 56:973–977
18.
19.
Jongen V, Briet J, De Jong R et al (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112:537–542CrossRefPubMed
20.
21.
22.
Lapidus RG, Ferguson AT, Ottaviano YL et al (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res Off J Am Assoc Cancer Res 2:805–810
23.
Lapidus RG, Nass SJ, Butash KA et al (1998) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Can Res 58:2515–2519
24.
Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mamm Gland Biol Neoplasia 3:85–94CrossRef
25.
26.
Liu X, Shi H (2015) Regulation of estrogen receptor α expression in the hypothalamus by sex steroids: implication in the regulation of energy homeostasis. Int J Endocrinol 2015:949085PubMedPubMedCentral
27.
Matorras R, Rodriguez F, Perez C et al (1996) Infertile women with and without endometriosis: a case control study of luteal phase and other infertility conditions. Acta Obstet Gynecol Scand 75:826–831CrossRefPubMed
28.
Moeloek FA, Moegny E (1993) Endometriosis and luteal phase defect. Asia Ocean J Obstetr Gynaecol 19:171–176CrossRef
29.
Pandya KJ, Yeap BY, Weiner LM et al (2001) Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 24:43–46CrossRefPubMed
30.
Rendina GM, Donadio C, Fabri M et al (1984) Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 17:285–291CrossRefPubMed
31.
Rogers PA, D’hooghe TM, Fazleabas A et al (2009) Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci (Thousand Oaks, Calif) 16:335–346CrossRef
32.
Ross-Innes CS, Stark R, Holmes KA et al (2010) Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 24:171–182CrossRefPubMedPubMedCentral
33.
Thigpen T, Brady MF, Homesley HD et al (2001) Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19:364–367CrossRefPubMed
34.
Yue W, Yager JD, Wang JP et al (2013) Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 78:161–170CrossRefPubMed
Metadata
Title
Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue
Authors
Vanessa Toderow
Martina Rahmeh
Simone Hofmann
Verena Kirn
Sven Mahner
Udo Jeschke
Viktoria von Schönfeldt
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 2/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-017-4405-x

Other articles of this Issue 2/2017

Archives of Gynecology and Obstetrics 2/2017 Go to the issue

Gynecologic Endocrinology and Reproductive Medicine

No difference in mitochondrial distribution is observed in human oocytes after cryopreservation

Maternal-Fetal Medicine

Mifepristone vs balloon catheter for labor induction in previous cesarean: a randomized controlled trial

Maternal-Fetal Medicine

The impact of postpartum cervical tear on the occurrence of preterm birth in subsequent pregnancy

Gynecologic Endocrinology and Reproductive Medicine

Comparison of three treatment strategies for cesarean scar pregnancy

General Gynecology

Impact of surgery for endometriomas on pregnancy outcomes following in vitro fertilization-intracytoplasmic sperm injection. Who should be the preferred laparoscopists: gynecologists or reproductive surgeons?

Gynecologic Oncology

Value of endometrial thickness assessed by transvaginal ultrasound for the prediction of endometrial cancer in patients with postmenopausal bleeding